Tata in talks to launch Moderna COVID-19 vaccine in India - ET

It gave emergency-use approval to a vaccine by Bharat Biotech and state-run Indian Council of Medical Research and another licensed from Oxford University and AstraZeneca that is being produced by the Serum Institute. India has the world's second highest COVID-19 caseload after the United States, but daily cases have been declining since hitting a peak in September.

Reuters | Updated: 25-01-2021 10:28 IST | Created: 25-01-2021 10:21 IST
Tata in talks to launch Moderna COVID-19 vaccine in India - ET
Representative Image Image Credit: ANI

Tata Group's healthcare venture is said to have started initial discussions with Moderna Inc for a partnership to launch its COVID-19 vaccine in India, the Economic Times reported on Monday.

Tata Medical & Diagnostics could team up with India's Council of Scientific and Industrial Research to carry out clinical trials of Moderna's vaccine candidate in India, the report https://bit.ly/2Yd8E2B said, citing officials familiar with the matter. Moderna did not respond to Reuters request for comment outside business hours, while Tata Medical & Diagnostics did not immediately respond.

Unlike Pfizer's vaccine, which must be kept at minus 70 degrees Celsius or below, Moderna's can be stored at normal fridge temperatures, making it more suited for poorer countries such as India where cold chains are limited. Data released in November from Moderna's late-stage study showed it was 94.1% effective with no serious safety concerns. The shot was approved for use in the United States in December and in Europe earlier this month.

India mandates that any vaccine maker must conduct an additional local study if it has to be considered for what the country calls the world's biggest vaccination program. It gave emergency-use approval to a vaccine by Bharat Biotech and state-run Indian Council of Medical Research and another licensed from Oxford University and AstraZeneca that is being produced by the Serum Institute.

India has the world's second highest COVID-19 caseload after the United States, but daily cases have been declining since hitting a peak in September. India's drugs controller has said the overall efficacy of the AstraZeneca vaccine, locally branded COVISHIELD, was 70.42% based on trials done overseas, but the approval for Bharat Biotech's COVAXIN has faced criticism due to the lack of efficacy data.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)


TRENDING

OPINION / BLOG / INTERVIEW

Why unequal access to coronavirus vaccines is a threat to us all

... ...

India’s love affair with fossil fuels: the path to sustainable development?

... ...

Videos

Latest News

Biden: U.S. to launch massive effort to educate Americans about COVID-19 vaccines

U.S. President Joe Biden said on Thursday his administration plans to launch a campaign to educate Americans about coronavirus vaccines in anticipation of a period later this year where supply may outstrip demand because of vaccine hesitanc...

Soccer-Milan limp through on away goals after draw with Red Star

AC Milan progressed to the last 16 of the Europa League on away goals after struggling to a 1-1 draw at home to Red Star Belgrade on Thursday, with the visitors playing the final 20 minutes with 10 men as the tie finished 3-3 on aggregate.M...

Boeing to pay $6.6 million to FAA over safety lapses

Boeing Co agreed Thursday to pay 6.6 million in penalties to the Federal Aviation Administration FAA after U.S. regulators said it failed to comply with a 2015 safety agreement and cited other safety concerns. The penalties include 5.4 mill...

7 dead, 1 injured after prison outbreak in Haiti's capital

At least seven people were killed and one injured on Thursday after several inmates tried to escape from a prison in Haitis capital, witnesses said. The incident occurred in northeast Port-au-Prince at the Croix-des-Bouquets Civil Prison, w...

Give Feedback